The Recall Desk
ModerateFDA (Drugs)·D-1467-2019·Announced 2019-07-17

American Health Packaging Recalls Anastrozole Tablets Due to GMP Deviations

American Health Packaging is recalling Anastrozole Tablets due to potential cross-contamination from cleaning procedure failures.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity voluntary precautionary recall.

Plain-English summary

American Health Packaging is recalling Anastrozole Tablets, USP, 1 mg, in 30-count and 1000-count bottles. The recall affects 375,921 bottles distributed nationwide in the United States. The product is manufactured by Cadila Healthcare Ltd. for BluePoint Laboratories.

The recall was initiated due to Good Manufacturing Practice (GMP) deviations, specifically potential cross-contamination resulting from cleaning procedure failures. The affected lots include various expiration dates ranging from 2019 to 2020.

Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or healthcare provider for guidance on replacement or refund options.

The recalled product

Product
ANASTROZOLE (ANASTROZOLE)
Brand
ANASTROZOLE
Affected units
375,921

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (20)

  • Count
  • Lot
  • Expiry: [30-count bottle] Lots M711214
  • M711215
  • M711216
  • M711217
  • exp 8/31/2019
  • Lots M802198
  • M802199
  • exp 1/31/2020
  • Lots M805203
  • M805204
  • M805207
  • exp 3/31/2019
  • Lots M812455
  • exp 6/30/2020
  • Lot M815766
  • exp 9/30/2020
  • Lots M818633
  • M818634

UPCs (1)

  • 0368001155045

Distribution

Distributed nationwide across the United States.